Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA

Journal of the American Academy of Dermatology

Volumn 51, Issue 5, 2004, Pages 746-754

  Legat, Franz J ^a   Hofer, Angelika ^a   Quehenberger, Franz ^a   Kahofer, Peter ^a   Kerl, Helmut ^a   Wolf, Peter ^a,b  

^a Department of Dermatology   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; METHOXSALEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; MALE; PHOTOCHEMOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PUVA; RADIATION DOSE; RADIATION RESPONSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADMINISTRATION, ORAL; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOXSALEN; PROSPECTIVE STUDIES; PSORIASIS; PUVA THERAPY; TREATMENT OUTCOME;

EID: 8744267669     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.04.029     Document Type: Article

References (26)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 26:2001;314-320
2. Gottlieb A.B., Bos J.D. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol. 105:2002;105-116
3. Lebwohl M., Ali S. Treatment of psoriasis Part I. Topical therapy and phototherapy. J Am Acad Dermatol. 45:2001;487-498
4. Morison W.L. Phototherapy and photochemotherapy of skin disease. 2nd ed.:1991;Raven Press, New York
5. Calzavara-Pinton P.G., Hönigsmann H. Phototherapy of psoriasis. Hönigsmann H., Jori G., Young A.R. The fundamental bases of phototherapy. 1996;29-42 OEMF, Milano
6. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., Pathak M.A. Photochemotherapy of psoriasis with oral methoxypsoralen and longwave ultraviolet light. N Engl J Med. 291:1974;1207-1211
7. Melski J.W., Tanenbaum L., Parrish J.A., Fitzpatrick T.B., Bleich H.L. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 68:1977;328-335
8. Henseler T., Wolff K., Hönigsmann H., Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centers. Lancet. 1:1981;853-857
9. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol. 130:1994;246-255
10. Sakuntabhai A., Sharpe G.R., Farr P.M. Response of psoriasis to twice weekly PUVA. Br J Dermatol. 128:1993;166-171
11. Housman T.S., Rohrback J.M., Fleischer A.B., Feldman S.R. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 46:2002;557-559
12. Tanew A., Radakovic-Fijan S., Schemper M., Hönigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis. Arch Dermatol. 135:1999;519-524
13. Wolff K. Should PUVA be abandoned? N Engl J Med. 336:1997;1041-1045
14. Stern R.S., Thibodeau L.A., Kleinerman R.A., Parrish J.A., Fitzpatrick T.B. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med. 300:1979;809-813
15. Maier H., Schemper M., Ortel B., Binder M., Tanew A., Hönigsmann H. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology. 193:1996;185-191
16. Morison W.L., Baughman R.D., Day R.M., Forbes P.D., Hoenigsmann H., Krueger G.G., et al. Consensus workshop on the toxic effect of long-term PUVA therapy. Arch Dermatol. 134:1998;595-598
17. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): a meta-analysis. Arch Dermatol. 134:1998;1582-1585
18. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl J Med. 336:1997;1041-1045
19. Stern R.S. The PUVA follow up study: the risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 44:2001;755-761
20. Hofer A., Fink-Puches R., Kerl H., Wolf P. Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol. 138:1998;96-100
21. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., Ellis C.N., for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 47:2002;821-833
22. Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 157:1978;238-244
23. Collins P., Wainwright N.J., Amorim I., Lakshmipathi T., Ferguson J. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol. 135:1996;248-254
24. Tanew A., Ortel B., Hönigsmann H. Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis. J Am Acad Dermatol. 41:1999;408-413
25. Koebner H. Zur Atiologie der Psoriasis. Vjschr Dermatol. 3:1876;559
26. Ibbotson S.H., Farr P.M. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol. 113:1999;346-350